{"id":40360,"date":"2021-04-01T07:42:54","date_gmt":"2021-04-01T07:42:54","guid":{"rendered":"https:\/\/i-base.info\/htb\/?p=40360"},"modified":"2021-11-21T13:48:41","modified_gmt":"2021-11-21T13:48:41","slug":"bamlanivimab-prophylaxis-reduces-hospitalisation-and-mortality-results-from-phase-3-blaze-2-study","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/40360","title":{"rendered":"Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study"},"content":{"rendered":"

\"\"NOTE: Please see comment about lack of activity against recent variants.<\/em><\/strong><\/p>\n

Simon Collins, HIV i-Base<\/strong><\/p>\n

The BLAZE-2 study randomised 1175 residents or staff who were at high risk of COVID-19 through living or working in residential care homes to either bamlanivimab or placebo.<\/strong><\/p>\n

Of these, 966\/1175 were PCR negative, using bamlanivimab as prophylaxis and 209\/1175 were PCR positive, using the intervention as treatment.<\/p>\n

Participants in the prevention group needed to be PCR negative at baseline with a primary endpoint of incidence of COVID-19 symptoms and secondary endpoint of PCR-positive transmission, both at day 57.<\/p>\n

Full results presented at CROI 2021 showed an 80% reduced risk of symptoms: OR 0.20 (95%CI: 0.08 to 0.49), p<0.001.<\/p>\n

The top line results from this study had been released in a company press statement in January. [2]<\/p>\n

comment<\/h3>\n

Despite these positive results, bamlanivimab is not longer used for any indication.<\/strong><\/p>\n

This is because bamlanivimab loses sensitivity to variants that recently became dominant including Delta.<\/strong><\/p>\n

This is likely to be a similar concern for other antibodies developed against original strains of SARS-CoV-2.<\/strong><\/p>\n

References<\/p>\n

    \n
  1. Cohen M et al. Bamlanivimab prevents COVID-19 morbidity and mortality in nursing-home setting. CROI 2021, virtual. Oral abstract 121.
    \nhttps:\/\/www.croiconference.org\/abstract\/bamlanivimab-prevents-covid-19-morbidity-and-mortality-in-nursing-home-setting\/<\/a> (abstract and webcast)<\/li>\n
  2. Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study. HTB (24 February 2021).
    \n    https:\/\/i-base.info\/htb\/39886<\/a><\/li>\n<\/ol>\n

    This report was first published on 19 March 2021. It was updated in June 2021 to include the concern about loss of sensitivity to recent variants.<\/em><\/p>\n

    <\/h2>\n","protected":false},"excerpt":{"rendered":"

    NOTE: Please see comment about lack of activity against recent variants. Simon Collins, HIV i-Base The BLAZE-2 study randomised 1175 residents or staff who were at high risk of COVID-19 through living or working in residential care homes to either …<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,283,278],"tags":[307],"class_list":["post-40360","post","type-post","status-publish","format-standard","hentry","category-conference-reports","category-covid-19-investigational-drugs","category-covid-19","tag-croi-2021-virtual"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=40360"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/40360\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=40360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=40360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=40360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}